Medicine
Metopirone 250 mg capsule
Metopirone 250 mg capsule is a prescription medicine containing Metyrapone for oral use, marketed by Esteve Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store Metopirone bottles at room temperature 20°C to 25°C (68°F to 77°F)…
Key facts
- Active ingredient (INN)
- Metyrapone
- Brand
- Metopirone
- Strength
- 250 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 18 capsules
- Marketing authorisation holder
- Esteve Pharmaceuticals
- Manufacturers
- Esteve PharmaceuticalsHRA Pharma Rare Diseases
- Origin register
- US FDA, United States
- Storage
- Store Metopirone bottles at room temperature 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). Keep container tightly closed and protect from heat and moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V04CD01 Metyrapone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 25 January 1962
- Identifiers
- RxCUI 105450, 199772DailyMed set ID 4046b167-7a46-8f4a-e063-6394a90a147f, 3a27d0ef-83a7-4e1c-9430-46a3326ee8d8NDC 68118-455, 76336-455Application NDA012911
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 18 capsule, gelatin coated in 1 bottle | 68118-455-18 | Esteve Pharmaceuticals | 25 January 1962 |
| 18 capsule, gelatin coated in 1 bottle | 76336-455-18 | HRA Pharma Rare Diseases | 25 January 1962 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 4 December 1961 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Metyrapone is an adrenal steroid synthesis inhibitor indicated , in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. It is available as capsules for oral use. MedsAcross supplies Metyrapone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MetyraponeFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Metopirone prescribing information (Esteve Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Metopirone 250 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.